Moore Capital Management, LP Iveric Bio, Inc. Transaction History

Moore Capital Management, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$18.67 - $24.56 $723,630 - $951,921	-38,759 Reduced 18.46%	171,241 $4.17 Million
Q4 2022 Feb 14, 2023	SELL	$17.24 - $23.95 $516,234 - $717,158	-29,944 Reduced 12.48%	210,000 $4.5 Million
Q3 2022 Nov 14, 2022	BUY	$9.4 - $18.59 $2.26 Million - $4.46 Million	239,944 New	239,944 $4.31 Million
Q1 2022 May 16, 2022	SELL	$12.15 - $16.83 $836,272 - $1.16 Million	-68,829 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$13.83 - $18.78 $4.38 Million - $5.95 Million	-316,977 Reduced 82.16%	68,829 $1.15 Million

Q3 2021 Nov 15, 2021	BUY	$7.07 - $17.5 $2.73 Million - $6.75 Million	385,806 New	385,806 $6.27 Million

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Moore Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Moore Capital Management, LP with notifications on news.